MS

Biogen Idec submits Plegridy to FDA for multiple sclerosis patients with relapsed disease

Biogen Idec submits Plegridy to FDA for multiple sclerosis patients with relapsed disease

Yahoo/AP

XenoPort Sinks as Spasticity Drug For MS Fails in Trial

XenoPort Sinks as Spasticity Drug For MS Fails in Trial

Bloomberg

The Biogen MS Pill: The 'Holy Mother' Of All Drug Launches?

The Biogen MS Pill: The 'Holy Mother' Of All Drug Launches?

Pharmalot

Biogen MS Pill’s Early Sales May Help It Beat Estimates

Biogen MS Pill’s Early Sales May Help It Beat Estimates

Bloomberg

Biogen's MS Pill Roars Out Of Launch Gate

Biogen's MS Pill Roars Out Of Launch Gate

TheStreet.com

Biogen Hits Primary Endpoints in MS Study

Biogen Hits Primary Endpoints in MS Study

Motley Fool

Biogen Idec up after positive MS drug study

Biogen Idec up after positive MS drug study

Marketwatch

Elan completes sale of Tysabri stake to Biogen

Elan completes sale of Tysabri stake to Biogen

Reuters

Tecfidera Raises The Bar For Biogen Idec

Tecfidera Raises The Bar For Biogen Idec

Seeking Alpha

Biogen prices new MS drug at discount to key competitors

Biogen prices new MS drug at discount to key competitors

Reuters